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Objectives: To examine the effect of copper intrauterine device (Cu-IUD) on female sexual dysfunction
(FSD) subtypes.
Material and methods: There were 159 sexually active women (ninety Cu-IUD users and sixty-nine
women with no contraception) who attended the gynecology clinic for routine gynecologic control
informed about the study and asked to ﬁll Female Sexual Function Index (FSFI) and Beck Depression
Inventory questionnaires.
Results: The prevalence of FSD was 41.1% (n¼ 37) and 37.7% (n¼ 26) in Cu-IUD users and control groups,
respectively (p > 0.05). In analyses of mean overall and subgroup scores of FSFI, signiﬁcantly lower scores
for arousal (p¼ 0.021), lubrication (p¼ 0.021), orgasm (p¼ 0.040), pain (p < 0.001), and overall FSFI
(p¼ 0.031) were noted in Cu-IUD users. When the results for FSFI domains were considered for Cu-IUD
users separately, the only difference to reach statistical signiﬁcance, using a Bonferroni adjustment, was
found to be the pain domain. Finally, we determined that Cu-IUD status made the strongest unique
contribution to explaining the dependent variable pain in multiple logistic regression model (b ¼ 0.26,
p¼ 0.001).
Conclusion: Cu-IUD users have increased sexual pain compared to women with no contraception, which
in turn possibly causes decreased sexual arousal, lubrication, and orgasm in these women.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Long-term reversible contraception success, safety, cost-
affectivity, and suitability for all reproductive ages are important
factors that make copper intrauterine device (Cu-IUD) use the most
commonly preferredmethod after sterilization [1]. According to the
World Health Organization, approximately 162 million women
(23% of all contraceptive users) choose IUD for contraception,
especially in less developed regions [2]. However, IUD use may
create some undesired side effects such as increased menstrual
bleeding, intermenstrual spotting, and pelvic discomfort [3].s and Gynecology, Akdeniz
y.
an@akdeniz.edu.tr (S. Olgan).
bstetrics & Gynecology. PublishedFemale sexual dysfunction (FSD) can be divided into subtypes
and are characterized by a lack of or diminished sexual feelings of
interest, fantasies, and thoughts or by problems becoming aroused,
lubricated, or having an orgasm although adequately stimulated, or
with feelings of pain in connection with intercourse [4]. Today,
satisfactory sexual habits is conﬁrmed as one of the fundamental
components of health and quality of life, but unfortunately 43% of
women complain of at least one sexual problem [5]. Despite this
huge rate, sexual dysfunction has not recently received much in-
terest among the cluster of prominently investigated topics in
modern gynecology.
There are few data in the literature dealing with the effects of
Cu-IUD on sexual function issues. We therefore conducted this
controlled study in order to address weaknesses in the information
thus far available. Our primary objective was to examine the effect
of Cu-IUD on FSD subtypes.by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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This cross-sectional study was approved with the number 156/
2010 by the institutional review board of Gulhane Military Acad-
emy, Ankara, Turkey. Women with Cu-IUDs, who attended our
gynecology clinic from January 2012 to March 2012 for routine
gynecologic control, were consecutively identiﬁed upon their pre-
sentation and were informed about the study. Inclusion criteria
that women were sexually active between the ages of 20 years and
40 years; and had a monogamic and heterosexually active rela-
tionship lasting for longer than 4 weeks. The control group con-
sisted of women with no contraception (either using traditional
methods or desiring pregnancy) within the same period.
A total of 254 sexually active women, aged 20e40 years,
attended our gynecology clinic during the study period, but 88
were excluded due to a history of: systemic disease (n ¼ 10; hy-
pertension, diabetes mellitus, rheumatologic pathologies, etc.),
previous pelvic surgery (n ¼ 8; hysterectomy, anterioreposterior
and apical repair, incontinence surgery), premature menopause [6]
(n ¼ 1); infertility [7] (n¼ 3); and early pregnancy (n¼ 2). Twenty
six women did not want to ﬁll the questionnaire. Also excluded
were ﬁve patients who had urinary or anal incontinence symptoms,
were diagnosed with Grade 2 or more genital prolapsus according
to POP-Q classiﬁcation, cystitis, previously known urethral disor-
ders, or interstitial cystitis due to their possible confounding effects
[8]. Together with the patients with pelvic infection, pelvic
congestion, or already known endometriosis (n¼ 4), the patients
with vulvodynia and vaginismus (n¼ 2) were also not included in
the study [8]. Moreover patients receiving oral contraceptives and
therapeutics that may interfere with sexual functioning (e.g. sed-
atives, antidepressants and b blockers; n ¼ 27) were excluded
(Figure 1).
After the initial evaluation, the women who were found to be
eligible for the study were instructed to ﬁll the Female Sexual
Function Index (FSFI) and the Beck Depression Inventory (BDI). The
study protocol was explained, privacy assured, and voluntary
participation emphasized. Written, informed consent was obtainedAssessed for eligibility  
(n = 254) 
Selected cases 
Cu-IUD users (n = 92) 
n = 2 
*missing paƟents 
Final analysis 
Cu-IUD users (n = 90) 
Excluded (n = 88) due to: 
• TherapeuƟcs (n = 27) 
• Refused to parƟcipate (n = 26) 
• History of systemic disease (n = 10) 
• Previous pelvic surgery (n = 8) 
• Premature menopause (n = 1) 
• InferƟlity (n = 3) 
• Early pregnancy (n = 2) 
• Urinary–anal inconƟnence/genital 
prolapsus/known urological pathology 
(n = 5) 
• Known pelvic inflammatory disease or 
endometriosis (n = 4) 
• Known vulvodynia/vaginismus (n = 2)  
Selected cases 
Control group (n = 74) 
n = 5 
*missing paƟents 
Final analysis 
Control group (n = 69) 
Figure 1. Flow chart of the participants in the study. *missing patients due to
incompletely ﬁlled questionnaires. Cu-IUD ¼ copper intrauterine device.from all volunteers. Then the women self-completed the ques-
tionnaire in a separate room allowing for sufﬁcient privacy. One of
the authors was available if additional information about the
questions was requested. Seven patients (5 from that control group
and 2 from the Cu-IUD users) were removed from the study due to
incomplete questionnaires. Finally, the study group included 90
and the control group 69 sexually active women (Figure 1).
Data of each volunteer's age, partner's age, body mass index,
parity, duration of marriage, smoking habits, educational status
(primary, high school, university), profession, income, living habitat
(city, village), Cu-IUD status, and duration of Cu-IUDwere recorded.
All patients' serum luteinizing hormone, follicle-stimulating hor-
mone (FSH), thyroid stimulating hormone, free testosterone, pro-
lactin, and estradiol levels were measured.
The FSFI is a reliable, valid, and anonymously developed ques-
tionnaire with six domains (desire, subjective arousal, lubrication,
orgasm, satisfaction, pain) and 19 questions for self-reported
measurement of female sexual function [9]. Each domain is
assigned a minimum and a maximum score, and the total score for
sexual function is determined from all domains. A score 26.5 is
accepted as FSD [10]. A higher score for individual domain or a
higher total score indicates better sexual functioning. The Turkish
version of the FSFI has been shown to be reliable and valid for the
Turkish population [11].
BDI is a 21-questionmultiple-choice self-report inventory that is
a commonly used tool in measuring either the presence or the
severity of depression [12]. Each question has a 4-point scale
answerwith respect to the intensity (0e3) and the total score range
is 0e63. BDI was previously re-arranged for the Turkish population
and the cut-off value was determined as17 [13]. We also accepted
a patient with ‘depression’ when she had a result 17.
The clinical features of both groups were compared, and the
potential correlation between the FSFI and clinical parameters was
evaluated. Parametric data of the patients were compared by in-
dependent samples t test (reported as mean ± standard deviation)
and nonparametric data by c2 and ManneWhitney U tests (re-
ported as median, range). Potential correlation between patients'
demographic characteristics, hormone proﬁles, Cu-IUD status, BDI
scores, and FSFI domain scores were evaluated by Spearman rank
order correlation. A one-way between groups multivariate analysis
of variance was performed to investigate effect of Cu-IUD on FSFI
domain scores. Multiple logistic regression analysis was used to
examine the association between pain scores and independent
variables. All the statistical analyses were performed using SPSS
(version 22.0; SPSS Inc., Chicago, IL, USA). The level of signiﬁcance
was set at p < 0.05.
Results
Cu-IUD users and control individuals had similar mean age,
partner age, body mass index, parity, and duration of marriage, and
similar distribution of educational level completed, income, living
habitat, employment, and smoking history (Table 1). The
mean ± standard deviation duration of Cu-IUD among study group
was 4.0 ± 1.8 years. In relation to hormonal status, higher levels of
estradiol and FSH were determined in the Cu-IUD users (Table 2).
Although in both groups the number of women with FSD was
similar, themean FSFI scores were found to be signiﬁcantly lower in
Cu-IUD users than control participants. Dealing with each of the
FSFI domains; arousal, lubrication, orgasm, and pain scores were
signiﬁcantly lower in Cu-IUD users. There was no signiﬁcant dif-
ference in the mean BDI scores and the distribution of womenwith
depression (Table 3).
The relationship between age, BDI, and FSFI domains were
investigated using Spearman rank order correlation coefﬁcient. BDI
Table 1
Sociodemographic characteristics of the control individuals and Cu-IUD users.
Control
n¼ 69
Cu-IUD users
n¼ 90
p
Age (y) 32.97 ± 4.88 34.26 ± 4.29 ns
Partner age (y) 35.35 ± 5.02 36.50 ± 4.56 ns
BMI (kg/m2) 26.53 ± 3.10 26.66 ± 3.36 ns
Parity 2.0 (1.0e4.0) 2.0 (1.0e6.0) ns
Duration of marriage, years 11.64 ± 5.51 11.54 ± 4.90 ns
Education completed Primary school
(8 y)
20 (29.0) 40 (44.4) ns
High school (11 y) 35 (50.7) 32 (35.6)
College (12 y) 14 (20.3) 18 (20.0)
Income 1000 YTL 42 (60.9) 56 (62.2) ns
>1000 YTL 27 (39.1) 34 (37.8)
Living habitat Village 11 (15.9) 13 (14.4) ns
City 58 (84.1) 77 (85.6)
Employment House wife 48 (69.6) 66 (73.3) ns
Employed 21 (30.4) 24 (26.7)
Smoking Positive 59 (85.5) 75 (83.3) ns
Negative 10 (14.5) 15 (16.7)
Data are presented as mean ± standard deviation, median (range), or n (%).
BMI ¼ body mass index; ns ¼ nonsigniﬁcant; YTL ¼ Turkish Lira.
Table 3
Female Sexual Function Index (FSFI) and Beck Depression Inventory (BDI) scores.
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found to be correlated with arousal, orgasm, and pain, while Cu-
IUD status was found to be correlated with arousal, lubrication,
orgasm, and pain. There was a negative weak correlation between
age, BDI, and pain score, while a negative signiﬁcant correlation at
middle level was found between pain score and Cu-IUD status
(r ¼ 0.301, p < 0.001; the presence of Cu-IUD associated with
lower pain score; Table 4).
A one-way between groups multivariate analysis of variance
was performed to investigate effect of Cu-IUD on FSFI domain
scores. Six FSFI domains (desire, arousal, lubrication, orgasm,
satisfaction and pain) were used as dependent variables of MAN-
OVA. The independent variable was Cu-IUD status. Preliminary
assumption testing was conducted to check for normality, linearity,
univariate and multivariate outliers, homogeneity of var-
ianceecovariance matrices, and multicollinearity, with no serious
violations noted. There was a statistically signiﬁcant difference
between Cu-IUD users and nonusers on the combined dependent
variables, F (6, 152) ¼ 3.17, p ¼ 0.006; Wilks' l ¼ 0.89; partial
h2 ¼ 0.11. When the results for the dependent variables were
considered separately, the only difference to reach statistical sig-
niﬁcance, using a Bonferroni adjusted a level of 0.008, was pain: F
(1, 157) ¼ 15.62, p < 0.001, partial h2 ¼ 0.09. An inspection of the
mean ± standard deviation scores indicated that Cu-IUD users re-
ported lower levels of pain scores (4.05 ± 0.08) than control par-
ticipants (4.52 ± 0.09).
All signiﬁcant ﬁndings for FSFI domain of pain in correlation
analysis then were entered into multiple logistic regression model.
The FSH and estradiol levels were also added into the same modelTable 2
Hormone proﬁles of control subjects and copper intrauterine device (Cu-IUD) users.
Control
n¼ 69
Cu-IUD users
n¼ 90
p
LH (mIU/mL) 5.3 (2.8e9.1) 5.3 (2.8e11.3) ns
FSH (mIU/mL) 5.2 (2.8e11.4) 5.8 (3.5e9.6) 0.003
Free testesterone (pg/mL) 1.5 (0.7e2.6) 1.3 (0.5e2.7) ns
Prolactin (ng/mL) 8.9 (3.2e21.6) 9.0 (3.2e23.4) ns
Estradiol (pg/mL) 43.0 (14.5e157.2) 49.3 (19.3e157.2) 0.044
TSH (uIU/mL) 1.6 (0.9e3.1) 1.7 (0.9e4.8) ns
Data are presented as median (range).
FSH¼ follicle-stimulating hormone; LH¼ luteinizing hormone; ns¼ nonsigniﬁcant;
TSH ¼ thyroid stimulating hormone.as they might have been possible confounding factors. As shown in
Table 5, the results indicated that age (b¼0.18, p¼ 0.018), Cu-IUD
status (b ¼ 0.29, p¼ 0.001), and BDI score (b ¼ 0.18, p¼ 0.018)
were still signiﬁcant contributing factors to FSFI domain of pain. In
this model, the largest b coefﬁcient was 0.29, which is Cu-IUD
usage.
Due to the lack of information from previous studies, we
calculated the statistical power for the current study after the data
analysis. Using a web-based power calculation program, we ob-
tained the statistical power value of 97.8%with an a error level of 5%
for Cu-IUD status and FSFI domain of pain.Discussion
FSD is associated with interpersonal, psychological, physiolog-
ical, medical, social, and cultural factors [14]. According to pub-
lished epidemiological studies, the prevalence estimate of having at
least one sexual dysfunction in women is around 40% [5]. Consis-
tent with the current literature, FSD was diagnosed in 37.7% of our
control group and 41% of Cu-IUD users.
Although the number of women with sexual disorders was not
higher in Cu-IUD users, signiﬁcantly lower scores for arousal,
lubrication, orgasm, pain, and overall FSFI were noted which
conﬁrmed lower sexual functioning (the interpretation of partial
results is a linear dependence; the lower the scores the worse the
sexual functioning within a given category). In line with previous
literature reporting high co-morbidity between different sexual
problems, as well as substantial overlap between the dimensions,
high domain intercorrelations were also found in our study
(Table 4). Consequently we investigated the effect of Cu-IUD status
on each of FSD categories, in detail. When the results for FSFI do-
mains were considered separately, the only difference to reach
statistical signiﬁcance, using a Bonferroni adjustment, was found to
be pain. It seems that presence of Cu-IUD effects pain more than
arousal, lubrication and orgasm scores. We consider that pain
initially might cause related worsening in arousal/lubrication/
orgasm; and loss of arousal/lubrication/orgasm associated with
dyspareunia, subsequently might contribute to the worsening of
coital pain over time. We, therefore, conducted our further analyses
solely based on pain scores as an outcome variable for all interre-
lated factors.
Age, BDI score, and Cu-IUD status were found to be correlated
with FSFI domain of pain. Our ﬁndings showed that there was a
signiﬁcant negative correlation between the patient's age and pain
score, which conﬁrmed the worse sexual functioning for pain in
older patients. According to the literature, ﬁndings regarding the
impact of age on female sexual function are somewhat inconsistent.Control
n¼ 69
Cu-IUD users
n¼ 90
p
FSFI domain score
Desire 4.8 (1.2e6.0) 4.8 (1.8e6.0) ns
Arousal 5.1 (2.7e6.0) 4.9 (2.1e6.0) 0.021
Lubrication 5.1 (1.8e6.0) 4.8 (2.1e6.0) 0.021
Orgasm 4.4 (0.8e6.0) 4.0 (2.0e6.0) 0.040
Satisfaction 4.8 (3.2e6.0) 4.8 (2.0e6.0) ns
Pain 4.4 (3.0e6.0) 4.0 (2.0e6.0) <0.001
Total FSFI score 28.6 (18.3e34.2) 27.3 (17.1e32.9) 0.031
No. of women with sexual disorder 26 (37.7) 37 (41.1) ns
BDI score 12 (6.0e21.0) 12.0 (6.0e21.0) ns
No. of women with depression 7 (10.1) 10 (11.1) ns
Data are presented as median (range) or n (%).
ns ¼ nonsigniﬁcant.
Table 4
Spearman rank order correlations between age, Cu-intrauterine device (IUD) status, Female Sexual Function Index (FSFI), and Beck Depression Inventory (BDI) domains.
Age IUD
status
BDI Desire Arousal Lubrication Orgasm Satisfaction Pain
IUD Status 0.148
BDI 0.017 0.082
Desire 0.119 0.080 0.286*
Arousal 0.170* 0.184* 0.341* 0.580*
Lubrication 0.115 0.183* 0.419* 0.448* 0.671*
Orgasm 0.175* 0.164* 0.198* 0.400* 0.565* 0.547*
Satisfaction 0.114 0.056 0.318* 0.360* 0.406* 0.481* 0.384*
Pain 0.188* 0.301* 0.218* 0.321* 0.441* 0.440* 0.429* 0.412*
FSFI 0.181* 0.172* 0.418* 0.710* 0.825* 0.793* 0.749* 0.675* 0.628*
* The signiﬁcance rate was accepted to be p  0.05, and r values are presented.
M. Sakinci et al. / Taiwanese Journal of Obstetrics & Gynecology 55 (2016) 30e34 33A number of population-based studies have reported no age related
increase in the incidence of FSD [5,15]. Conversely, pain problems
were reported to be more frequent in younger patients
(20e40 years), while problems with lubrication increased signiﬁ-
cantly after 40 years of age [16]. Similarly, Abdo et al reported that
pain seemed to decrease with age [17]. However, the age spectrum
of our study population diverges from these studies mostly because
it consists of women of reproductive age (33.7 ± 4.6 years) but not
perimenopause or menopause. Since sexual function differs
throughout the lifespan, it is reasonable to assume that the effect
would change depending on the age spectrum of the particular
study.
Consistent with the literature, we also found that higher the BDI
scores were associated with lower the scores for FSFI domain of
pain. It was found that all dimensions of sexual function, except for
desire, had an association with somatization, depression, anxiety,
and panic as measured by the brief symptom inventory-18. All the
associations were negative, that is, the more symptoms of psy-
chological distress, the more problems with sexual function [18].
Other studies have reported that there was a signiﬁcant correlation
between presence of FSD and depression [19]. In fact, depressed
women might suffer from several symptoms including affective
and somatic symptoms. These symptoms all contribute to FSD since
they might cause mood and desire disorders [20].
In order to determine the real signiﬁcance of Cu-IUD status on
pain scores, multiple logistic regression analysis was performed.
Age, BDI, and Cu-IUD status all remained their signiﬁcance when
performing multiple logistic regression analysis. We found that Cu-
IUD status made the strongest unique contribution to explaining
the dependent variable pain, when the variance explained by all
other variables in the model controlled for. The effects of age and
BDI were found to be slightly lower, indicating that they made less
of a unique contribution.
Analyzing the available literature, it seems that too little atten-
tion is paid to the effect of intrauterine devices, and in particular
those Cu-IUDs, on sexual functioning. Most clinical research evalu-
ating this issue generally focuses on the comparison of levonorges-
trel intrauterine systems and oral contraceptives, evaluated side
effects other than dyspareunia or not used validated scales. SmallTable 5
Multiple regression analysis to explain Female Sexual Function Index domain of
pain.
Standardized coefﬁcient b 95% CI p
Age 0.184 0.057 to 0.005 0.018
FSH (mIU/mL) 0.116 0.019 to 0.128 ns
Estradiol (pg/mL) 0.024 0.003 to 0.004 ns
Cu-IUD status 0.290 0.692 to 0.212 0.001
BDI 0.180 0.072 to 0.007 0.018
BDI¼ Beck Depression Inventory; CI ¼ conﬁdence interval; Cu-IUD ¼ copper in-
trauterine device; FSH ¼ follicle-stimulating hormone; ns ¼ nonsigniﬁcant.number of studies investigated the effect of Cu-IUD on female sexual
functioning. Skrzypulec et al [21] investigated sexual functioning of
women using contraceptive methods. However, their primary
outcome measure was to determine the effect of levonorgestrel
containing intrauterine devices. They considered women using
different type of intrauterine device and no contraception as control.
In detailed analysis, statistically signiﬁcant differences between
groups were found in categories: sexual desire, arousal, orgasm,
satisfaction, and dyspareunia, which conﬁrmed higher sexual func-
tioning in women with the Mirena system. Concerning the pain
subscale, the Mirena group had signiﬁcantly higher scores than IUD
and control group while there were no difference in pain scores
between Cu-IUD users and controls [21]. Similarly, Li et al [22] did
not ﬁnd any signiﬁcant changes in quality of life or sexual func-
tioning in groups of women using oral contraceptives, progestagen
injections, and IUDs. Moreover, no signiﬁcant difference was
revealed in any of the three Derogatis Sexual Functioning Inventory
subscale scores in the IUD group [22]. However, this inventory only
contains sexual satisfaction, drive, and body image subscales and
does not give information regarding dyspareunia. Mutlu et al [23]
compared uterine artery Doppler parameters to predict Cu-IUD
induced side effects. They observed no differences in pain scores
after 6 months of Cu-IUD insertion by using ﬁve-point Likert scales
[23]. Finally, as previously mentioned, none of these studies inves-
tigated Cu-IUD users with controls and none of them used FSFI
questionnaire. The FSFI is regarded as a gold standard measure of
female sexual functioning [24] and has been conﬁrmed and clinically
documented with regard to validity, sensitivity, reliability, internal
consistency, stability, and testeretest reliability in the diagnosing of
disorders in sexual desire [24,25], arousal [26], and orgasm [25,26]
as well as pain-related sexual disorders [26].
Sexual dysfunction is inﬂuenced by a variety of factors including
social features and religious beliefs of the community. It should
therefore be kept in mind that the results might be diverse in
different regions of the world. Because our study was restricted to
Turkish patients from a military hospital, it would be more
acceptable not to generalize these results and investigate this issue
in further studies.
Our ﬁndings indicated that Cu-IUD users might have decreased
sexual arousal, lubrication, orgasm, and, more importantly,
increased pain compared to women with no contraception. In this
study, however, the real effect of Cu-IUD on FSD might be under-
estimated since we did not consider the women whose Cu-IUDs
previously needed to be removed because of serious complaints.
Together with the basis of serious problems, we believe that Cu-IUD
would affect FSD and in particular the pain domain more.
It is clear that, prospective studies investigating Cu-IUD usage
on FSD are still needed by using validated methods. The possible
side effects should not reduce the worth of Cu-IUD for sure, but
provide counseling the patients.
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